---
document_datetime: 2025-11-23 14:36:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-zidovudine-teva.html
document_name: lamivudine-zidovudine-teva.html
version: success
processing_time: 0.1062274
conversion_datetime: 2025-12-28 13:55:43.160012
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lamivudine/Zidovudine Teva

[RSS](/en/individual-human-medicine.xml/66183)

##### Withdrawn

This medicine's authorisation has been withdrawn

lamivudine / zidovudine

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 9 March 2023, the European Commission withdrew the marketing authorisation for Lamivudine / Zidovudine Teva (lamivudine / zidovudine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Lamivudine / Zidovudine Teva was granted marketing authorisation in the EU on 28 February 2011 for treatment of HIV infection. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2015. The product had not been marketed in the EU since 2021.

Lamivudine / Zidovudine Teva is a generic medicine of Combivir.

The European Public Assessment Report (EPAR) for Lamivudine / Zidovudine Teva is updated to indicate that the marketing authorisation is no longer valid.

Lamivudine/Zidovudine Teva : EPAR - Summary for the public

English (EN) (658.94 KB - PDF)

**First published:** 15/03/2011

**Last updated:** 21/03/2023

[View](/en/documents/overview/lamivudinezidovudine-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-761)

български (BG) (755.24 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/bg/documents/overview/lamivudinezidovudine-teva-epar-summary-public_bg.pdf)

español (ES) (663.86 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/es/documents/overview/lamivudinezidovudine-teva-epar-summary-public_es.pdf)

čeština (CS) (732.81 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/cs/documents/overview/lamivudinezidovudine-teva-epar-summary-public_cs.pdf)

dansk (DA) (676.37 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/da/documents/overview/lamivudinezidovudine-teva-epar-summary-public_da.pdf)

Deutsch (DE) (665.21 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/de/documents/overview/lamivudinezidovudine-teva-epar-summary-public_de.pdf)

eesti keel (ET) (662.51 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/et/documents/overview/lamivudinezidovudine-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (759.09 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/el/documents/overview/lamivudinezidovudine-teva-epar-summary-public_el.pdf)

français (FR) (664.8 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/fr/documents/overview/lamivudinezidovudine-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (677.44 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/hr/documents/overview/lamivudinezidovudine-teva-epar-summary-public_hr.pdf)

italiano (IT) (662.83 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/it/documents/overview/lamivudinezidovudine-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (734.67 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/lv/documents/overview/lamivudinezidovudine-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (680.35 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/lt/documents/overview/lamivudinezidovudine-teva-epar-summary-public_lt.pdf)

magyar (HU) (727.6 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/hu/documents/overview/lamivudinezidovudine-teva-epar-summary-public_hu.pdf)

Malti (MT) (735.87 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/mt/documents/overview/lamivudinezidovudine-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (663.83 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/nl/documents/overview/lamivudinezidovudine-teva-epar-summary-public_nl.pdf)

polski (PL) (734.42 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/pl/documents/overview/lamivudinezidovudine-teva-epar-summary-public_pl.pdf)

português (PT) (664.69 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/pt/documents/overview/lamivudinezidovudine-teva-epar-summary-public_pt.pdf)

română (RO) (684.35 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/ro/documents/overview/lamivudinezidovudine-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (733.95 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sk/documents/overview/lamivudinezidovudine-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (723.86 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sl/documents/overview/lamivudinezidovudine-teva-epar-summary-public_sl.pdf)

Suomi (FI) (663.06 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/fi/documents/overview/lamivudinezidovudine-teva-epar-summary-public_fi.pdf)

svenska (SV) (659.65 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sv/documents/overview/lamivudinezidovudine-teva-epar-summary-public_sv.pdf)

## Product information

Lamivudine/Zidovudine Teva : EPAR - Product Information

English (EN) (1.02 MB - PDF)

**First published:** 15/03/2011

**Last updated:** 21/03/2023

[View](/en/documents/product-information/lamivudinezidovudine-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-345)

български (BG) (2.12 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/bg/documents/product-information/lamivudinezidovudine-teva-epar-product-information_bg.pdf)

español (ES) (1.05 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/es/documents/product-information/lamivudinezidovudine-teva-epar-product-information_es.pdf)

čeština (CS) (1.95 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/cs/documents/product-information/lamivudinezidovudine-teva-epar-product-information_cs.pdf)

dansk (DA) (1.02 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/da/documents/product-information/lamivudinezidovudine-teva-epar-product-information_da.pdf)

Deutsch (DE) (1.08 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/de/documents/product-information/lamivudinezidovudine-teva-epar-product-information_de.pdf)

eesti keel (ET) (1.04 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/et/documents/product-information/lamivudinezidovudine-teva-epar-product-information_et.pdf)

ελληνικά (EL) (2.16 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/el/documents/product-information/lamivudinezidovudine-teva-epar-product-information_el.pdf)

français (FR) (1.11 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/fr/documents/product-information/lamivudinezidovudine-teva-epar-product-information_fr.pdf)

hrvatski (HR) (1.12 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/hr/documents/product-information/lamivudinezidovudine-teva-epar-product-information_hr.pdf)

íslenska (IS) (1.03 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/is/documents/product-information/lamivudinezidovudine-teva-epar-product-information_is.pdf)

italiano (IT) (1.05 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/it/documents/product-information/lamivudinezidovudine-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.85 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/lv/documents/product-information/lamivudinezidovudine-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.11 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/lt/documents/product-information/lamivudinezidovudine-teva-epar-product-information_lt.pdf)

magyar (HU) (1.79 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/hu/documents/product-information/lamivudinezidovudine-teva-epar-product-information_hu.pdf)

Malti (MT) (1.98 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/mt/documents/product-information/lamivudinezidovudine-teva-epar-product-information_mt.pdf)

Nederlands (NL) (1.04 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/nl/documents/product-information/lamivudinezidovudine-teva-epar-product-information_nl.pdf)

norsk (NO) (1.02 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/no/documents/product-information/lamivudinezidovudine-teva-epar-product-information_no.pdf)

polski (PL) (1.85 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/pl/documents/product-information/lamivudinezidovudine-teva-epar-product-information_pl.pdf)

português (PT) (1.04 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/pt/documents/product-information/lamivudinezidovudine-teva-epar-product-information_pt.pdf)

română (RO) (1.21 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/ro/documents/product-information/lamivudinezidovudine-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.83 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sk/documents/product-information/lamivudinezidovudine-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.96 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sl/documents/product-information/lamivudinezidovudine-teva-epar-product-information_sl.pdf)

Suomi (FI) (1.03 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/fi/documents/product-information/lamivudinezidovudine-teva-epar-product-information_fi.pdf)

svenska (SV) (1.04 MB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sv/documents/product-information/lamivudinezidovudine-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0028 21/03/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lamivudine/Zidovudine Teva : EPAR - All Authorised presentations

English (EN) (593.06 KB - PDF)

**First published:** 15/03/2011

**Last updated:** 21/03/2023

[View](/en/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-998)

български (BG) (692.6 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/bg/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (599.43 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/es/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (646.79 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/cs/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (601.85 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/da/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (601.75 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/de/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (599.51 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/et/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (680.34 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/el/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (602.47 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/fr/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (601.12 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/hr/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (593.58 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/is/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (593.2 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/it/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (684.71 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/lv/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (668.5 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/lt/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (644.2 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/hu/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (674.67 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/mt/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (601.51 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/nl/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (600.87 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/no/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (648.5 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/pl/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (599.51 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/pt/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (665.61 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/ro/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (683.69 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sk/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (614.26 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sl/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (593.44 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/fi/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (599.3 KB - PDF)

**First published:**

15/03/2011

**Last updated:**

21/03/2023

[View](/sv/documents/all-authorised-presentations/lamivudinezidovudine-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lamivudine/Zidovudine Teva Active substance

- lamivudine
- zidovudine

International non-proprietary name (INN) or common name

- lamivudine
- zidovudine

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR01

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.

## Authorisation details

EMA product number EMEA/H/C/001236

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Teva Pharma B.V.

Opinion adopted 18/11/2010 Marketing authorisation issued 28/02/2011 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lamivudine/Zidovudine Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (809.43 KB - PDF)

**First published:** 08/08/2012

**Last updated:** 21/03/2023

[View](/en/documents/procedural-steps-after/lamivudinezidovudine-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Lamivudine/Zidovudine Teva : EPAR - Public assessment report

Adopted

English (EN) (874.37 KB - PDF)

**First published:** 15/03/2011

**Last updated:** 21/03/2023

[View](/en/documents/assessment-report/lamivudinezidovudine-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lamivudine/Zidovudine Teva

Adopted

Reference Number: EMA/725978/2010

English (EN) (621.75 KB - PDF)

**First published:** 19/11/2010

**Last updated:** 21/03/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lamivudinezidovudine-teva_en.pdf)

**This page was last updated on** 21/03/2023

## Share this page

[Back to top](#main-content)